Renzapride: A new drug for the treatment of constipation in the irritable bowel syndrome

Expert Opinion on Investigational Drugs

Volumn 17, Issue 11, 2008, Pages 1663-1670

  Scarpellini, Emidio ^a   Tack, Jan ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

5 hydroxytryptamine; Constipation; Irritable bowel syndrome; Renzapride

Indexed keywords

4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID 2 (DIETHYLAMINO)ETHYL ESTER; 4 AMINO 5 CHLORO N (OCTAHYDRO 6 METHYL 2H QUINOLIZIN 2 YL) ORTHO ANISAMIDE; 5 METHOXYTRYPTAMINE; BEMESETRON; CISAPRIDE; GASTRIN; GRANISETRON; METHYSERGIDE; METOCLOPRAMIDE; MOTILIN; ONDANSETRON; PLACEBO; RENZAPRIDE; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN 4 RECEPTOR; TROPISETRON; ZACOPRIDE; ZATOSETRON;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; AREA UNDER THE CURVE; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRANSIT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; IRRITABLE COLON; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PROLACTIN BLOOD LEVEL; QT PROLONGATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH PARESIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TORSADE DES POINTES;

ANIMALS; BENZAMIDES; BICYCLO COMPOUNDS, HETEROCYCLIC; CONSTIPATION; GASTRINS; HUMANS; IRRITABLE BOWEL SYNDROME; MOTILIN;

EID: 54949095492     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.11.1663     Document Type: Review

References (54)

1. Drossman DA. Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am J Med 1999;107:S41-50
2. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 400,000 subjects. Aliment Pharmacol Ther 2003;17:643-50
3. Locke GR. The epidemiology of functional gastrointestinal disorders in North America. Gastroenterol Clin North Am 1996;25:1-19
4. Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology 1990;99:409-15
5. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-31
6. Davidson HI, Pilot MA. Does endogenous neuronal 5-hydroxytryptamine influence canine intestinal motility? J Physiol 1986;376:49P
7. Bulbring E, Crema A. Observations concerning the action of 5-hydroxytryptamine on the peristaltic reflex. Br J Pharmacol 1958;13:444-57
8. Beubler E, Bukhave K, Rask-Madsen J. Significance of calcium for the prostaglandin E2-mediated secretory response to 5-hydroxytryptamine in the small intestine. Gastroenterology 1986;90:1972-7
9. Donowitz M, Asarkof N, Pike G. Calcium dependence of serotonin-induced changes in rabbit ileal electrolyte transport. J Clin Invest 1980;66:341-52
10. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007;132:397-414
11. Cremonini F, Delgado Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta analysis of randomized controlled trials. Neurogastroeterol Motil 2003;15:79-86
12. Muller Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmaco Ther 2001;15:1655-66
13. Tack J, Muller Lissner S, Bytzer P, et al. A randomized controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005;54:1707-13
14. Brejer MR, Akkermans LMA, Schuurkes JAJ. Gastrointestinal prokinetic benzamides: the pharmacology underlying of motility. Pharmacol Rev 1995;4:631-51
15. Dumuis A, Sebben M, Bockaert J. BRL 24924: a potent agonist at non classical 5-HT receptor positively coupled with adenylate cyclase in collicul neurons. Eur J Pharmacol 1989;162:381-4
16. 4 receptor agonists and gastric motility stimulants. J Med Chim 1993;36:683-9
17. Myers NL, Palmer RMJ, Wray HA, et al. Effects of single doses of renzapride on gastrointestinal motility in healthy subjects. Gut 2002;51:A137
18. Camilleri M, McKinzie S, Fox J, et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004;2:895-904
19. Staniforth DH, Pennick M. Human pharmacology of renzapride: a new gastrokinetic benzamide without dopamine agonist properties. Eur J Clin Pharmacol 1990;38:161-4
20. Gaddum JH, Picarelli ZP. Two kinds of tryptamine receptor. Br J Pharmacol Chemother 1957;12:323-8
21. Butler A, Hill JM, Ireland SJ, et al. Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors. Br J Pharmacol 1988;94:397-412
22. 4) positively coupled to adenylate cyclase in neurons. Naunyn Schmeidebergs Arch Pharmacol 1989;340:403-10
23. 4 receptor activation. Br J Pharmacol 1991; 102:563-4
24. 4 receptors. Eur J Pharmacol 1991;205:203-8
25. Baxter GS, Craig DA, Clarke DE. 5-hydroxytryptamine 4 receptors mediate relaxation of the rat oesophagus tunica muscolaris mucosae. Naunyn Schmeidebergs Arch Pharmacol 1991;343:439-46
26. 3 and 'atypical' 5HT receptors mediating guinea pig ileal contractions. Br J Pharmacol 1990;101:513-20
27. 4 receptors mediate inhibition and facilitation of fast synaptic transmission in enteric neurons. Am J Physiol 1994;266:G230-80
28. 4 receptors. Naunyn Schmeidebergs Arch Pharmacol 1995; 351:229-36
29. Tack J, Janssens J, Vantrappen G, Wood J. Actions of 5-hydroxytriptamine on myenteric neurons in guinea pig gastric antrum. Am J Physiol 1992;263:G838-46
30. 4-receptor mediated facilitation of the emptying phase of the peristaltic reflex in the guinea pig isolated ileum. Br J Pharmacol 1993;110:1572-8
31. 4 receptor activation facilitates recovery from synaptic rundown and increases transmitter release from single varicosities of myenteric neurons. Am J Physiol Gastrointest Liver Physiol 2008;294:G1376-83
32. 3 receptor antagonists in modulation of visceral hypersensitivity. Br J Pharmacol 1995;114:558-62
33. Gullikson GW, Virnia R, Loeffler R, Erwin WD. Alfa2-adrenergic model of gastroparesis: a validation with renzapride, a stimulatory of motility. Am J Physiol 1991;261:G426-32
34. Song CW, Lee KY, Kim CD, et al. Effect of cisapride and renzapride on gastrointestinal motility and plasma concentration in dogs. J Pharmacol Exp Ther 1997;281:1312-6
35. Galligan JJ, Vanner S. Basic and clinical pharmacology of new motility promoting agents. Neurogastr Motil 2005;17:643-53
36. Mackie AD, Ferrington C, Cowan S, et al. The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis. Aliment Pharmacol Ther 1991;5:135-42
37. Tack J, Middletone SJ, Horne MC, et al. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation predominant bowel syndrome. Aliment Pharmacol Ther 2006;23:1655-65
38. Spiller RC, Meyers NL, Hickling RI. Identification of patients with non-D, non-C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled clinical trial. Dig Dis Sci 2008
39. George AM, Meyers NL, Hickling RI. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome: multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting. Aliment Pharmacol Ther 2008;27:830-7
40. Naliboff BD, Berman S, Chang L, et al. Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 2003;124:1738-47
41. Koch KM, Palmer JL, Noordin N, et al. Sex and age differences in the pharmacokinetics of alosetron. Br J Clin Pharmacol 2002;53:238-42
42. 3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome. Neurogastroenterol Motil 2005;17:212-21
43. Alyzime press release. April 2008. Available from: http://www.alizyme.com/alizyme/media/press/show.jsp?ref=128 [Last accessed 2008 September 3]
44. Meyers NL, Hickling RI. The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome. J Int Med Res 2007;35:848-66
45. Potet F, Bouyssou T, Escande D, Baro' I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac ether-à-go go channel. J Pharm Exp Ther 2001;299:1007-12
46. Cooper SM, McClelland CM, McRitchie B, Turner DH. BRL 24924: a new and potent gastric motility stimulant. Br J Pharmacol 1988;383P
47. Meyers NL, Hickling R. Pharmacology and metabolism of renzapride: a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R&D 2008;9:37-63
48. 3 receptor antagonist. Dig Dis Sci 1999;44:20-4
49. 3-receptor antagonist in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7:175-80
50. 3 receptor antagonist alosetron inhibits the colorectal distension-induced depressor response and spinal c-fos expression in the anaesthetized rat. Gut 2000;46:474-80
51. Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type-3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001
52. 3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990;35:477-80
53. Delvaux M, Louvel D, Mamet JP, et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998;12:849-55
54. Patel SM, Stason WB, Legedza A, et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005;17:332-40